Literature DB >> 15458909

Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners.

Susan R Johnson1.   

Abstract

The management of adverse premenstrual symptoms has presented a difficult challenge for clinicians. However, based on numerous well-designed research studies over the last decade, we now have diagnostic criteria for the severe form of the syndrome, premenstrual dysphoric disorder, and a variety of evidence-based therapeutic strategies. This review presents a comprehensive, practical description of what the clinician needs to know to diagnose and treat adverse premenstrual symptoms at all levels of severity. Diagnostic criteria are described in detail, including a discussion of the distinction between premenstrual dysphoric disorder and premenstrual syndrome (PMS). The rationale for including prospective symptom calendars as a routine part of the diagnostic evaluation of severe symptoms is presented. The differential diagnosis of cyclic symptoms, including depression and anxiety disorders, menstrual migraine, and mastalgia, and an approach for the management of each of these problems are presented. A treatment approach is recommended that matches the treatment to the degree of problems the woman is experiencing. Serotonin reuptake inhibitors are the treatment of choice for severe symptoms, and most women with PMS/premenstrual dysphoric disorder will respond to intermittent, luteal phase-only therapy. Ovulation suppression should be reserved for women who do not respond to other forms of therapy. The role of oophorectomy is limited, and guidelines for its use are presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458909     DOI: 10.1097/01.AOG.0000140686.66212.1e

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  22 in total

Review 1.  Gynecological management of premenstrual symptoms.

Authors:  Lee P Shulman
Journal:  Curr Pain Headache Rep       Date:  2010-10

Review 2.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Perceived stress and severity of perimenstrual symptoms: the BioCycle Study.

Authors:  Audra L Gollenberg; Mary L Hediger; Sunni L Mumford; Brian W Whitcomb; Kathleen M Hovey; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

4.  Dietary B vitamin intake and incident premenstrual syndrome.

Authors:  Patricia O Chocano-Bedoya; JoAnn E Manson; Susan E Hankinson; Walter C Willett; Susan R Johnson; Lisa Chasan-Taber; Alayne G Ronnenberg; Carol Bigelow; Elizabeth R Bertone-Johnson
Journal:  Am J Clin Nutr       Date:  2011-02-23       Impact factor: 7.045

Review 5.  Progesterone for premenstrual syndrome.

Authors:  Olive Ford; Anne Lethaby; Helen Roberts; Ben Willem J Mol
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

6.  The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Sarah Canning; Mitch Waterman; Nic Orsi; Julie Ayres; Nigel Simpson; Louise Dye
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

7.  Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study.

Authors:  Elizabeth R Bertone-Johnson; Brian W Whitcomb; Stacey A Missmer; JoAnn E Manson; Susan E Hankinson; Janet W Rich-Edwards
Journal:  J Womens Health (Larchmt)       Date:  2014-08-06       Impact factor: 2.681

Review 8.  Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Authors:  Caroline Fenton; Keri Wellington; Marit D Moen; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD).

Authors:  Kazuo Yamada; Eiichiro Kamagata
Journal:  Qual Life Res       Date:  2017-07-03       Impact factor: 4.147

10.  A prospective study of caffeine and coffee intake and premenstrual syndrome.

Authors:  Alexandra C Purdue-Smithe; JoAnn E Manson; Susan E Hankinson; Elizabeth R Bertone-Johnson
Journal:  Am J Clin Nutr       Date:  2016-07-06       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.